FAS and the risk of diabetic retinopathy in patients with type 2 diabetes mellitus
- 1Department of Medical Technology, Jiangxi Medical College
- 2Department of Laboratory Medicine, Central Hospital of Shangrao City
- 3Department of General Practice, Shangrao People’s Hospital
Abstract
Background: Chronic inflammation is considered to play an important role in the development and progression of diabetic retinopathy (DR). In this study, we investigated the predictive value of a score constructed from fibrinogen and albumin for DR risk and identified individuals with well-controlled glycated hemoglobin A1c (HbA1c) who remain at high risk of DR.
Methods: Discovery and validation cohorts, which included 715 patients with type 2 diabetes mellitus (T2DM), were enrolled in the study. Peripheral biomarkers (platelets, neutrophils, monocytes, lymphocytes, fibrinogen, albumin, and HbA1c) were detected, and we investigated the predictive value and risk-stratified roles of 10 inflammatory biomarkers in the two cohorts.
Results: In the discovery cohort, neutrophil-to-lymphocyte ratio (NLR), fibrinogen-to-albumin ratio (FAR), and fibrinogen-to-albumin score (FAS) were significantly associated with the risk of DR, and FAS showed the highest discriminatory ability. The predictive performance of FAS for DR, in terms of area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), was 0.69, 0.83, 0.43, 0.42, and 0.83 in the discovery cohort, and 0.69, 0.82, 0.42, 0.47, and 0.77 in the validation cohort, respectively. When FAS was added to a base model, the resulting model (model 4) achieved an AUC of 0.80 in the discovery cohort and 0.76 in the validation cohort. Model 4 showed good calibration and high net benefit, and net reclassification improvement (NRI)/integrated discrimination improvement (IDI) analyses confirmed the incremental predictive value of FAS. Subgroup analyses by age, estimated glomerular filtration rate (eGFR), hypertension, and insulin therapy showed no significant interactions, indicating that FAS is a robust predictive biomarker across these subgroups. When stratified by HbA1c, patients with low FAS and well-controlled HbA1c had the lowest DR rate, whereas those with a FAS score of 2 had the highest DR rates.
Conclusion: FAS is a robust and independent predictive biomarker for DR, with consistent performance across subgroups, including in patients with well-controlled HbA1c.
Related
- The association between diabetic retinopathy and cognitive impairment in patients with diabetes mellitus: a systematic review and meta-analysis
- Corneal endothelial changes in type 2 diabetes mellitus: a systematic review and meta-analysis with subgroup comparisons by diabetic retinopathy status and disease duration
- Correlation between serum uric acid-to-creatinine ratio and diabetic retinopathy in type 2 diabetes mellitus patients
- Risk factors for diabetic peripheral neuropathy in diabetes mellitus patients: A case-control study.
- Prior Cardiovascular Disease and Incident Diabetic Retinopathy in Newly Diagnosed Type 2 Diabetes Mellitus
BibTeX
@article{ye2026risk,
title = {{FAS and the risk of diabetic retinopathy in patients with type 2 diabetes mellitus}},
author = {Qiu-Ying Ye and Ming-Feng Fu and Yu-Lin Qiu and Qing Ye and Lu-Lu Zhan and Yi-Feng Yu and Ying Hu},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.1964487},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1964487/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - FAS and the risk of diabetic retinopathy in patients with type 2 diabetes mellitus
AU - Qiu-Ying Ye
AU - Ming-Feng Fu
AU - Yu-Lin Qiu
AU - Qing Ye
AU - Lu-Lu Zhan
AU - Yi-Feng Yu
AU - Ying Hu
PY - 2026
DA - 2026/11/05
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1964487
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1964487/full
AB - Background: Chronic inflammation is considered to play an important role in the development and progression of diabetic retinopathy (DR). In this study, we investigated the predictive value of a score constructed from fibrinogen and albumin for DR risk and identified individuals with well-controlled glycated hemoglobin A1c (HbA1c) who remain at high risk of DR. Methods: Discovery and validation cohorts, which included 715 patients with type 2 diabetes mellitus (T2DM), were enrolled in the study. Peripheral biomarkers (platelets, neutrophils, monocytes, lymphocytes, fibrinogen, albumin, and HbA1c) were detected, and we investigated the predictive value and risk-stratified roles of 10 inflammatory biomarkers in the two cohorts. Results: In the discovery cohort, neutrophil-to-lymphocyte ratio (NLR), fibrinogen-to-albumin ratio (FAR), and fibrinogen-to-albumin score (FAS) were significantly associated with the risk of DR, and FAS showed the highest discriminatory ability. The predictive performance of FAS for DR, in terms of area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), was 0.69, 0.83, 0.43, 0.42, and 0.83 in the discovery cohort, and 0.69, 0.82, 0.42, 0.47, and 0.77 in the validation cohort, respectively. When FAS was added to a base model, the resulting model (model 4) achieved an AUC of 0.80 in the discovery cohort and 0.76 in the validation cohort. Model 4 showed good calibration and high net benefit, and net reclassification improvement (NRI)/integrated discrimination improvement (IDI) analyses confirmed the incremental predictive value of FAS. Subgroup analyses by age, estimated glomerular filtration rate (eGFR), hypertension, and insulin therapy showed no significant interactions, indicating that FAS is a robust predictive biomarker across these subgroups. When stratified by HbA1c, patients with low FAS and well-controlled HbA1c had the lowest DR rate, whereas those with a FAS score of 2 had the highest DR rates. Conclusion: FAS is a robust and independent predictive biomarker for DR, with consistent performance across subgroups, including in patients with well-controlled HbA1c.
SN - 1664-2392
ER -